Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice.
Saved in:
| Title: | Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice. |
|---|---|
| Authors: | Maruyama Y; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan; Department of Otorhinolaryngology-Head and Neck Surgery, Showa Medical University School of Medicine, Tokyo, Japan., Hosonuma M; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Toyoda H; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan; Department of Orthopaedic Surgery, School of Medicine, Showa Medical University, Tokyo, Japan., Funayama E; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan; Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa Medical University, Tokyo, Japan., Sasaki A; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Baba Y; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan., Tajima K; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan., Nakashima R; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan., Sasaki A; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Shida M; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan., Tsurui T; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Tsuji M; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Shimane T; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Head and Neck Oncology Center, Showa Medical University, Tokyo, Japan., Kiuchi Y; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Yoshimura K; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Kuramasu A; Department of Clinical Immuno Oncology, Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan. Electronic address: atsuok@med.showa-u.ac.jp. |
| Source: | European journal of pharmacology [Eur J Pharmacol] 2025 Jul 15; Vol. 999, pp. 177704. Date of Electronic Publication: 2025 May 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
